Immunologic study of fibrinogen and its split products in venous thrombosis.
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001772:Blood Cell Count; D001792:Blood Platelets; D005017:Ethyl Biscoumacetate / Q000627:therapeutic use; D005032:Ethylestrenol / Q000627:therapeutic use; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005340:Fibrinogen / Q000032:analysis*; D005342:Fibrinolysis; D005455:Fluorescent Antibody Technique; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D010629:Phenformin / Q000627:therapeutic use; D010690:Phlebography; D010973:Platelet Adhesiveness; D011655:Pulmonary Embolism / Q000276:immunology; D011720:Pyrazoles / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors
D000925:Anticoagulants; D011720:Pyrazoles; D005017:Ethyl Biscoumacetate; D005337:Fibrin; D005340:Fibrinogen; D006493:Heparin; D005032:Ethylestrenol; D010629:Phenformin